Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease acute pancreatitis
Comorbidity C0011860|type 2 diabetes
Sentences 15
PubMedID- 20682680 acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
PubMedID- 26059826 Clinical and nonclinical studies have implicated glucagon-like peptide-1 (glp-1) receptor agonist therapy as a risk factor for acute pancreatitis in patients with type 2 diabetes.
PubMedID- 26269615 Glucagon-like peptide-1 (glp-1) receptor agonist therapy has been implicated as a possible risk factor for acute pancreatitis in patients with type 2 diabetes.
PubMedID- 24859164 acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.
PubMedID- 24622714 Larger studies are needed to clarify whether age or type of incretin therapy could affect the risk of acute pancreatitis in patients with type 2 diabetes.
PubMedID- 24651798 That study used a large insurance database of more than 1 million people, and reported increased odds of hospitalizations for acute pancreatitis in patients with type 2 diabetes 64 years of age or younger that were prescribed either exenatide or saxagliptin.
PubMedID- 20412332 Recent case reports of acute pancreatitis in patients with type 2 diabetes (t2dm) treated with incretin-based therapies have triggered interest regarding the possibility of a mechanism-based association between pancreatitis and glucagon-like peptide-1 mimetics or dipeptidyl peptidase-4 (dpp-4) inhibitors.
PubMedID- 24764569 Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
PubMedID- 23440284 Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
PubMedID- 23300896 Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a japanese hospital database.
PubMedID- 20833867 The results of this study confirm the excess risk of acute pancreatitis associated with type 2 diabetes previously reported in other observational studies (2,4,5).
PubMedID- 26512613 To investigate the effects of dipeptidyl peptidase-4 (dpp-4) inhibitors on the risk of acute pancreatitis in patients with type 2 diabetes.this nationwide population-based cohort study used the diabetes patients dataset of taiwan's national health research insurance research database.
PubMedID- 25918533 If pancreatic autoantibodies are negative, patients have secondary diabetes due to pancreatitis or type 2 diabetes complicated by acute pancreatitis.
PubMedID- 21525466 Up-to-date observational reports and clinical study data revealed that 44 cases of acute pancreatitis occurred in patients with type 2 diabetes while taking exenatide (8 cases during clinical development and 36 postmarketing reports), 4 cases of pancreatitis in liraglutide-treated patients (in clinical trials), and none during therapy with albiglutide or taspoglutide (51).
PubMedID- 21577242 Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in taiwan.

Page: 1